Hypothalamic obesity in patients with craniopharyngioma: profound changes of several weight regulatory circuits
- PMID: 22654811
- PMCID: PMC3356147
- DOI: 10.3389/fendo.2011.00049
Hypothalamic obesity in patients with craniopharyngioma: profound changes of several weight regulatory circuits
Abstract
One of the most striking examples of dysfunctional hypothalamic signaling of energy homeostasis is observed in patients with hypothalamic lesions leading to hypothalamic obesity (HO). This drastic condition is frequently seen in patients with craniopharyngioma (CP), an embryological tumor located in the hypothalamic and/or pituitary region, frequently causing not only hypopituitarism, but also leading to damage of medial hypothalamic nuclei due to the tumor and its treatment. HO syndrome in CP patients is characterized by fatigue, decreased physical activity, uncontrolled appetite, and morbid obesity, and is associated with insulin and leptin resistance. Mechanisms leading to the profoundly disturbed energy homeostasis are complex. This review summarizes different aspects of important clinical studies as well as data obtained in rodent studies. In addition a model is provided describing how medial hypothalamic lesion can interact simultaneously with several weight-regulating circuitries.
Keywords: autonomous nervous system; gut hormones; hyperphagia; hypothalamic lesion; morbid obesity; neuropeptides.
Figures




Similar articles
-
Hypothalamic Obesity in Craniopharyngioma Patients: Disturbed Energy Homeostasis Related to Extent of Hypothalamic Damage and Its Implication for Obesity Intervention.J Clin Med. 2015 Sep 9;4(9):1774-97. doi: 10.3390/jcm4091774. J Clin Med. 2015. PMID: 26371051 Free PMC article. Review.
-
Acquired hypothalamic obesity: A clinical overview and update.Diabetes Obes Metab. 2024 Apr;26 Suppl 2:34-45. doi: 10.1111/dom.15530. Epub 2024 Mar 7. Diabetes Obes Metab. 2024. PMID: 38450938
-
Treatment of Acquired Hypothalamic Obesity: Now and the Future.Front Endocrinol (Lausanne). 2022 Apr 6;13:846880. doi: 10.3389/fendo.2022.846880. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35464063 Free PMC article. Review.
-
Appetite-regulating hormone changes in patients with craniopharyngioma.Obesity (Silver Spring). 2011 Jan;19(1):36-42. doi: 10.1038/oby.2010.80. Epub 2010 Apr 8. Obesity (Silver Spring). 2011. PMID: 20379145 Clinical Trial.
-
A novel rodent model that mimics the metabolic sequelae of obese craniopharyngioma patients.Pediatr Res. 2011 Mar;69(3):230-6. doi: 10.1203/PDR.0b013e3182083b67. Pediatr Res. 2011. PMID: 21372758 Free PMC article.
Cited by
-
Treatment of Hypothalamic Obesity With GLP-1 Analogs.J Endocr Soc. 2024 Nov 14;9(1):bvae200. doi: 10.1210/jendso/bvae200. eCollection 2024 Nov 26. J Endocr Soc. 2024. PMID: 39703362 Free PMC article. Review.
-
Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.Eur J Endocrinol. 2022 May 9;186(6):687-700. doi: 10.1530/EJE-21-0972. Eur J Endocrinol. 2022. PMID: 35294397 Free PMC article. Clinical Trial.
-
Resting energy expenditure in children at risk of hypothalamic dysfunction.Endocr Connect. 2022 Jul 21;11(8):e220276. doi: 10.1530/EC-22-0276. Print 2022 Aug 1. Endocr Connect. 2022. PMID: 35904233 Free PMC article.
-
Semaglutide treatment of hypothalamic obesity - a real-life data study.Pituitary. 2024 Oct;27(5):685-692. doi: 10.1007/s11102-024-01429-5. Epub 2024 Aug 9. Pituitary. 2024. PMID: 39120810 Free PMC article.
-
Craniopharyngioma - a childhood and adult disease with challenging characteristics.Front Endocrinol (Lausanne). 2012 Jul 4;3:80. doi: 10.3389/fendo.2012.00080. eCollection 2012. Front Endocrinol (Lausanne). 2012. PMID: 22783224 Free PMC article. No abstract available.
References
-
- Abbott C. R., Monteiro M., Small C. J., Sajedi A., Smith K. L., Parkinson J. R., Ghatei M. A., Bloom S. R. (2005). The inhibitory effects of peripheral administration of peptide YY(3-36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway. Brain Res. 1044, 127–13110.1016/j.brainres.2005.03.011 - DOI - PubMed
-
- Balbo S. L., Bonfleur M. L., Carneiro E. M., Amaral M. E., Filiputti E., Mathias P. C. (2002). Parasympathetic activity changes insulin response to glucose and neurotransmitters. Diabetes Metab. 28, 3S13–3S17; discussion 3S108–3S112. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous